Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumours
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …

Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity,
especially in genetic alteration and microenvironment. Conventional therapeutic strategies …

Immunotherapy has only limited efficacy against pancreatic ductal adenocarcinoma (PDAC)
due to the presence of an immunosuppressive tumor-associated stroma. Here, we …

In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a
critical role in determining tumor expansion, antitumor immunity, and the response to …

The development of cancer is a multi-step process involving the gradual loss of regulation
over the growth and functional capabilities of normal cells. Much research has been focused …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …

Immunotherapy has revolutionized cancer treatment in the last decade, and strategies to re-
activate cytotoxic immunity are now standard of care in several malignancies. Despite rapid …

Pancreatic cancer (pancreatic ductal adenocarcinoma, PDA) is infamously moving to the top
of the list as one of the most lethal cancers with an overall 5 year survival rate of 7%. Multiple …

Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic
development for cancer treatment. However, many cancer patients do not respond to …

The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) is non-
immunogenic, which consists of the stellate cells, fibroblasts, immune cells, extracellular …